Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022
February 14, 2022 at 04:01 pm EST
Share
Omnicell, Inc. provided earnings guidance for the first quarter and full year of 2022. For the quarter, the company expects total GAAP and non-GAAP revenues to be between $312 million and $318 million. The company expects first quarter 2022 GAAP and non-GAAP product revenues to be between $216 million and $219 million, and first quarter 2022 GAAP and non-GAAP service revenues to be between $96 million and $99 million.
For the year, the company expects total GAAP and non-GAAP revenues to be between $1.385 billion and $1.410 billion. The company expects full year 2022 GAAP and non-GAAP product revenues to be between $950 million and $965 million, and full year 2022 GAAP and non-GAAP service revenues to be between $435 million and $445 million.
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Companyâs XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
OMNICELL, INC. 
